AXL and endometrial carcinoma: Our data show that whereas 24% (15/63) of normal specimens expressed high levels of AXL (score 2, or 3), 63% (180/287) of primary type I and type II endometrial carcinoma samples and 86% (286/332) of endometrial cancer in all stages (primary tumors and metastases) expressed AXL (P<0.0001 for both, Table 1).